SHINE Technologies has signed a distribution agreement with Modawina Medical Company, expanding access to its non-carrier-added lutetium-177 (n.c.a. Lu-177), branded as Ilumira, in the United Arab Emirates.

The Janesville, Wisconsin-based company said the agreement marks its first entry into the UAE and extends its presence across the Europe, Middle East, and Africa regions. Modawina will distribute Ilumira to radiopharmaceutical manufacturers and nuclear medicine centers throughout the country.

Lutetium-177 is a key isotope used in targeted radiopharmaceutical therapies for cancer. Its ability to deliver radiation directly to cancerous cells while sparing healthy tissue has made it a growing focus in precision oncology, particularly in the treatment of metastatic prostate cancer.
Ilumira is produced at SHINE’s Cassiopeia facility, which the company says is among the highest-capacity Lu-177 production sites in North America. The facility is designed to produce up to 100,000 patient doses annually, according to the company.

Greg Piefer, founder and CEO of SHINE, said the UAE represents a promising growth area for advanced cancer treatments. “What’s most exciting about expanding into the UAE with MMC, a partner with deep relationships with healthcare providers across the region, is the opportunity to deliver breakthrough cancer treatments for patients who may not have had access before,” Piefer said.

The agreement reflects a broader strategy by SHINE to build out its global supply network for medical isotopes, a field experiencing heightened demand as radiopharmaceutical therapies become more widely adopted in oncology.

Molecular Imaging Homepage